Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ingelman-Sundberg

Showing results (211-220 of 278) with videos related to

Pageof 28
Sort By:
Archives of Toxicology|January 1, 1996
The role of CYP2E1 and 2B1 in metabolic activation of benzene derivativesI Gut, V Nedelcheva, P Soucek, et al.
The Journal of Nutrition|December 1, 1995
CYP-2E1 inhibitors partially ameliorate the changes in hepatic fatty acid composition induced in rats by chronic administration of ethanol and a high fat dietM Morimoto, R C Reitz, R J Morin, et al.
Biochemical and Biophysical Research Communications|March 13, 2001
Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43A Westlind, S Malmebo, I Johansson, et al.
The Pharmacogenomics Journal|December 11, 2013
High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductaseM-Y Lee, P Borgiani, I Johansson, et al.
Journal of Biochemical and Molecular Toxicology|March 31, 1999
Drug metabolizing enzymes in lymphocytesJ L Raucy, M Ingelman-Sundberg, S Carpenter, et al.
Clinical Pharmacology and Therapeutics|June 21, 2012
UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systemsT Haslemo, I Loryan, N Ueda, et al.
Pharmacogenetics|December 1, 1992
Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancerM Ingelman-Sundberg, I Johansson, I Persson, et al.
Carcinogenesis|December 1, 1991
Immunochemical localization and functional characterization of cytochrome P450IIE1 in rat hepatocyte foci and nodulesA B Kobusch, D Schrenk, G Gans, et al.
Environmental Health Perspectives|December 1, 1996
Phase II metabolism of benzeneD Schrenk, A Orzechowski, L R Schwarz, et al.
Clinical Neuropharmacology|January 1, 1992
Interethnic differences in drug oxidation. Implications for the utilization of antidepressants and neurolepticsM L Dahl, I Johansson, Q Y Yue, et al.
Pageof 28

Showing results (211-220 of 278) with videos related to

Sort By:
Pageof 28
Archives of Toxicology|January 1, 1996
The role of CYP2E1 and 2B1 in metabolic activation of benzene derivativesI Gut, V Nedelcheva, P Soucek, et al.
The Journal of Nutrition|December 1, 1995
CYP-2E1 inhibitors partially ameliorate the changes in hepatic fatty acid composition induced in rats by chronic administration of ethanol and a high fat dietM Morimoto, R C Reitz, R J Morin, et al.
Biochemical and Biophysical Research Communications|March 13, 2001
Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43A Westlind, S Malmebo, I Johansson, et al.
The Pharmacogenomics Journal|December 11, 2013
High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductaseM-Y Lee, P Borgiani, I Johansson, et al.
Journal of Biochemical and Molecular Toxicology|March 31, 1999
Drug metabolizing enzymes in lymphocytesJ L Raucy, M Ingelman-Sundberg, S Carpenter, et al.
Clinical Pharmacology and Therapeutics|June 21, 2012
UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systemsT Haslemo, I Loryan, N Ueda, et al.
Pharmacogenetics|December 1, 1992
Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancerM Ingelman-Sundberg, I Johansson, I Persson, et al.
Carcinogenesis|December 1, 1991
Immunochemical localization and functional characterization of cytochrome P450IIE1 in rat hepatocyte foci and nodulesA B Kobusch, D Schrenk, G Gans, et al.
Environmental Health Perspectives|December 1, 1996
Phase II metabolism of benzeneD Schrenk, A Orzechowski, L R Schwarz, et al.
Clinical Neuropharmacology|January 1, 1992
Interethnic differences in drug oxidation. Implications for the utilization of antidepressants and neurolepticsM L Dahl, I Johansson, Q Y Yue, et al.
Pageof 28